Ticker > Company >

Brooks Laboratories share price

Brooks Laboratories Ltd.

NSE: BROOKS BSE: 533543 SECTOR: Pharmaceuticals & Drugs  21k   17   1

127.41
-1.77 (-1.37%)
NSE: Today, 02:54 PM

Price Summary

Today's High

₹ 132.19

Today's Low

₹ 124

52 Week High

₹ 198.86

52 Week Low

₹ 73.25

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

375.31 Cr.

Enterprise Value

379.66 Cr.

No. of Shares

2.95 Cr.

P/E

211.93

P/B

3.22

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  39.52

CASH

0.69 Cr.

DEBT

5.04 Cr.

Promoter Holding

59.06 %

EPS (TTM)

₹  0.6

Sales Growth

43.12%

ROE

2.42 %

ROCE

3.5%

Profit Growth

118.68 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year43.12%
3 Year0.95%
5 Year7.63%

Profit Growth

1 Year118.68%
3 Year28.02%
5 Year16.03%

ROE%

1 Year2.42%
3 Year-3.33%
5 Year-10.76%

ROCE %

1 Year3.5%
3 Year-1.94%
5 Year-3.77%

Debt/Equity

0.0725

Price to Cash Flow

-38.77

Interest Cover Ratio

2.84

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 59.06 0.00
Sep 2024 63.59 0.00
Jun 2024 63.59 0.00
Mar 2024 63.59 0.00
Dec 2023 63.59 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of -10.3443 days.
  • The company has a high promoter holding of 59.06%.

 Limitations

  • The company has shown a poor revenue growth of 0.945032962018622% for the Past 3 years.
  • Company has a poor ROE of -3.32918265351531% over the past 3 years.
  • Company has a poor ROCE of -1.94293341307955% over the past 3 years
  • Company has contingent liabilities of 70.7904 Cr.
  • Company has negative cash flow from operations of -9.6806.
  • The company has a low EBITDA margin of -1.71810171585633% over the past 5 years.
  • The company is trading at a high PE of 211.93.
  • The company is trading at a high EV/EBITDA of 75.3585.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 21.75 17.72 17.93 20.79 38.45
Total Expenditure 20.65 17.34 17.65 19.28 36.59
Operating Profit 1.1 0.38 0.28 1.51 1.86
Other Income 0.16 0.65 0.07 0.2 0.1
Interest 0.21 0.27 0.16 0.32 0.45
Depreciation 0.44 0.46 0.4 0.43 0.78
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.6 0.3 -0.21 0.96 0.72
Tax 0.03 0 0 0 0
Profit After Tax 0.58 0.3 -0.21 0.96 0.72
Adjusted EPS (Rs) 0.22 0.12 -0.08 0.36 0.28

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 69.69 77.27 76.97 55.54 79.49
Total Expenditure 73.61 76.33 75.09 61.35 76.43
Operating Profit -3.92 0.95 1.87 -5.81 3.06
Other Income 0.41 0.96 0.95 0.12 1.11
Interest 3.35 3.25 0.67 0.77 0.84
Depreciation 6.65 7.09 1.49 1.72 1.77
Exceptional Items 0 0 0 0 0
Profit Before Tax -13.51 -8.44 0.67 -8.18 1.55
Tax 10.86 7.15 0 0 0.03
Net Profit -24.38 -15.59 0.67 -8.18 1.53
Adjusted EPS (Rs.) -9.77 -6.25 0.27 -3.28 0.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 24.7 24.7 24.7 24.7 26.25
Total Reserves 73.71 39.51 40.3 32.08 43.28
Borrowings 11.4 1.34 0 0 0
Other N/C liabilities 2.25 1.76 2.99 2.62 1.81
Current liabilities 45.8 25.69 35.46 33.02 23.05
Total Liabilities 157.86 93 103.45 92.42 94.39
Assets
Net Block 113.02 14.96 15.14 15.01 13.67
Capital WIP 0 0 1.12 0 0
Intangible WIP 0.11 0.02 0 0 0
Investments 0.02 46.81 46.84 46.85 46.86
Loans & Advances 6.68 3.04 3.1 2.79 2.68
Other N/C Assets 0.11 2.83 0.22 0.17 0.13
Current Assets 37.92 25.34 37.04 27.61 31.05
Total Assets 157.86 93 103.45 92.42 94.39
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -13.51 -8.44 0.67 -8.18 1.55
Adjustment 11.76 10.23 2.43 2.76 1.64
Changes in Assets & Liabilities -7.62 1.51 0.29 6.17 -13.07
Tax Paid -0.01 -4.2 -0.26 -0.19 0.2
Operating Cash Flow -9.39 -0.9 3.12 0.55 -9.68
Investing Cash Flow -2.33 -0.74 1.12 -0.4 0.18
Financing Cash Flow 9.61 1.31 -4.23 -0.21 9.6
Net Cash Flow -2.1 -0.33 0.02 -0.06 0.1

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 63.59 63.59 63.59 63.59 59.06
aryan mahajan 4.60 - 4.60 4.60 2.77
atul ranchal 23.86 23.86 23.86 23.86 21.60
davinder kumari 0.15 0.15 0.15 0.15 0.15
erwin mahajan 4.60 4.60 4.60 4.60 4.60
rajesh mahajan 19.48 19.48 19.48 19.48 19.48
rajni ranchal 3.28 3.28 3.28 3.28 3.28
saras gupta 3.07 3.07 3.07 3.07 2.63
savvy ranchal 3.00 3.00 3.00 3.00 3.00
selina ranchal 1.55 1.55 1.55 1.55 1.55
aryan majahan - 4.60 - - -
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 36.41 36.41 36.41 36.41 40.94
llp 0.40 0.46 0.50 0.20 0.24
one up financial consulta... - - - - 1.60
quant mutual fund-quant b... - - - 3.86 3.86
brj resources private - 1.60 1.60 - -
quant mutual fund - quant... 3.86 - 3.86 - -
quant mutual fund-busines... - 3.86 - - -
brj resources private lim... 1.60 - - - -

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Brooks Laboratories - Quaterly Results 13 Feb, 5:45 PM Brooks Laboratories - Quaterly Results 13 Feb, 5:45 PM Brooks Laboratories informs about newspaper publications 21 Dec, 12:26 PM Brooks Laboratories - Quaterly Results 9 Nov, 4:36 PM Brooks Laboratories - Quaterly Results 9 Nov, 4:36 PM Brooks Laboratories - Quaterly Results 9 Nov, 4:36 PM Brooks Laboratories - Quaterly Results 14 Aug, 5:42 PM Brooks Laboratories - Quaterly Results 18 May, 5:41 PM Brooks Laboratories - Quaterly Results 18 May, 5:41 PM Brooks Laboratories - Quaterly Results 18 May, 5:41 PM Brooks Laboratories informs about compliance certificate 4 Apr, 5:40 PM Brooks Laboratories - Quaterly Results 31 Jan, 6:05 PM Brooks Laboratories - Quaterly Results 31 Jan, 6:05 PM Brooks Laboratories - Quaterly Results 31 Jan, 6:05 PM Brooks Laboratories informs about board meeting 24 Jan, 5:09 PM Brooks Laboratories informs about press release 1 Sep, 3:50 PM Brooks Laboratories - Quaterly Results 10 Aug, 4:28 PM Brooks Laboratories - Quaterly Results 10 Aug, 4:28 PM Brooks Laboratories informs about resignation of director 8 Jul, 10:47 AM Brooks Laboratories informs about disclosure 3 Jun, 2:55 PM Brooks Laboratories informs about clarification 3 May, 4:50 PM Brooks Laboratories informs about compliance certificate 11 Apr, 4:30 PM Brooks Laboratories informs about postal ballot report 4 Mar, 3:36 PM Brooks Laboratories informs about notice of postal ballot 25 Nov, 4:29 PM Brooks Laboratories - Quaterly Results 14 Nov, 6:39 PM Brooks Laboratorie informs about updates 22 Aug, 2:53 PM Brooks Laboratories’ arm gets USFDA’s nod for Meropenem Injection 22 Aug, 9:20 AM Brooks Laboratories informs about outcome of board meeting 10 Aug, 4:49 PM Brooks Laboratories - Quaterly Results 10 Aug, 3:05 PM Brooks Laboratories’ arm gets marketing authorization in UK by MHRA 23 May, 1:00 PM Brooks Laboratories’ arm enters into distribution and supply agreement with Armas Pharmaceuticals 10 May, 2:39 PM Brooks Laboratories informs about trading window closure 23 Mar, 4:47 PM Brooks Laboratories’ arm gets marketing authorization for Meropenem in Germany 29 Nov, 3:30 PM Brooks Laboratories informs about trading window closure 29 Sep, 3:24 PM Brooks Laboratories acquires 44.33% stake in SteriBrooks Penems 18 Sep, 9:50 AM Brooks Laboratories partners with SteriScience 17 Sep, 4:52 PM Brooks Laboratories informs about outcome of board meeting 13 Apr, 11:00 AM

Brooks Laboratories Stock Price Analysis and Quick Research Report. Is Brooks Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Brooks Laboratories and its performance over the period of time. Brooks Laboratories stock price today is Rs 127.41.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Brooks Laboratories cash from the operating activity was Rs -9.6806 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Brooks Laboratories has a Debt to Equity ratio of 0.0725 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Brooks Laboratories , the EPS growth was 117.7534 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Brooks Laboratories has OPM of 3.84796838692551 % which is a bad sign for profitability.
     
  • ROE: Brooks Laboratories have a poor ROE of 2.4205 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Brooks Laboratories is Rs 127.41. One can use valuation calculators of ticker to know if Brooks Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Brooks Laboratories
X